Portal de Periódicos da CAPES

Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain

2021; Taylor & Francis; Volume: 14; Issue: 2 Linguagem: Inglês

10.1080/17512433.2021.1875819

1751-2441

Esther Chamorro‐de‐Vega, Carmen-Guadalupe Rodriguez-Gonzalez, Silvia Manrique‐Rodríguez, Elena Lobato‐Matilla, F Garcia-Moreno, María Olmedo, Rafael Correa‐Rocha, Maricela Valerio, Teresa Aldámiz‐Echevarría, Marina Machado, Milagros Sancho-González, Juan Carlos Lopez-Bernaldo-de-Quirós, Paula Ruiz-Briones, Rosa Romero‐Jiménez, Camino Sarobe-González, Álvaro Giménez‐Manzorro, Roberto Collado‐Borrell, Cecilia M. Fernández-Llamazares, José Luis Revuelta-Herrero, Beatriz Somoza-Fernández, S García Sánchez, Irene Taladriz-Sender, Emilio Bouza, Ana Herranz, Patricia Muñóz, María Sanjurjo‐Sáez,

Antibiotic Use and Resistance

Background: We report the long-term outcomes, changes in laboratory parameters, the incidence of secondary nosocomial infections and treatment cost of a Spanish cohort of patients with severe COVID-19 that received tocilizumab (TCZ).